Citius Oncology highlighted Phase 1 data for LYMPHIR combined with pembrolizumab showing 24% overall response rate and 20.5 months median progression-free survival in heavily pre-treated patients with recurrent or refractory gynecologic malignancies. The positive clinical signals in checkpoint inhibitor-resistant tumors support continued development of this immunomodulatory approach.